This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sebastiani, V. Articles by Iacobuzio-Donahue, C. A. Search for Related Content PubMed PubMed Citation Articles by Sebastiani, V. Articles by Iacobuzio-Donahue, C. A.

Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival

Authors' Affiliations: ¹ Department of Pathology, University "La Sapienza," Rome, Italy; Departments of ² Oncology and ³ Pathology, Johns Hopkins Hospital, Baltimore, Maryland; and ⁴ Department of Surgery, Jefferson Medical College, Philadelphia, Pennsylvania

Requests for reprints: Christine A. Iacobuzio-Donahue, Department of Gastrointestinal/Liver Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, 720 Rutland Street, Ross 632, Baltimore, MD 21205. Phone: 410-955-3511; Fax: 410-614-0671; E-mail: ciacobu{at}jhmi.edu.

Gemcitabine is considered the standard first-line therapy for patients with advanced pancreatic cancer. More recent strategies have focused on improving the efficacy of gemcitabine by either improving the method of delivery or by combining gemcitabine with other non-cross-resistant chemotherapy agents or with small-molecule drugs. However, the clinical benefits, response rates, and duration of responses have been modest. Deoxycytidine kinase (dCK) is the rate-limiting enzyme involved in the metabolism of gemcitabine. The expression of dCK has been postulated to be correlative of gemcitabine resistance. We determined the relationship of dCK immunohistochemical protein expression and/or genetic status of dCK in a panel of human pancreatic cancer tissues and pancreatic cancer cell lines and determined the relationship of these variables to the clinical outcome of patients treated with gemcitabine. We report that dCK protein expression is expressed in the majority of pancreatic cancers analyzed (40 of 44 cases, 91%) and showed a range of labeling intensities ranging from 1+ (labeling weaker in intensity than normal lymphocytes present in same section) to 3+ (labeling greater in intensity than normal lymphocytes present in same section). When labeling intensity was compared with survival, low dCK expression (1+ labeling) was correlated with both overall survival (P < 0.009) and progression-free survival following gemcitabine treatment (P < 0.04). Low dCK labeling intensity was also significantly correlated with patient age (70.3 ± 8.1 versus 59.8 ± 7.4 years; P < 0.0006), suggesting that age-related methylation of the dCK gene may account in part for the observed differences. Sequencing of the entire dCK coding sequence in 17 cell lines and 9 patients' cancer tissues with disease progression while on gemcitabine did not identify any mutations, suggesting that genetic alterations of dCK are not a common mechanism of resistance to gemcitabine for this tumor type. Moreover, dCK labeling showed similar patterns and intensities of labeling among matched pretreatment and post-treatment tissues. In summary, pretreatment levels of dCK protein are most correlated with overall survival following gemcitabine treatment and are stable even after resistance to gemcitabine is clinically documented.

This article has been cited by other articles:

				M Candelaria, D Gallardo-Rincon, C Arce, L Cetina, J. Aguilar-Ponce, O Arrieta, A Gonzalez-Fierro, A Chavez-Blanco, E de la Cruz-Hernandez, M. Camargo, et al. A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann. Onc., September 1, 2007; 18(9): 1529 - 1538. [Abstract] [Full Text] [PDF]

				Y. Mita, T. Ajiki, T. Kamigaki, T. Okazaki, H. Hori, H. Horiuchi, K. Hirata, T. Fujita, T. Fujimori, and Y. Kuroda Antitumor Effect of Gemcitabine on Orthotopically Inoculated Human Gallbladder Cancer Cells in Nude Mice Ann. Surg. Oncol., April 1, 2007; 14(4): 1374 - 1380. [Abstract] [Full Text] [PDF]

				L. Johnson, R. Lai, C. Santos, L. Dabbagh, and J. Mackey Unexpected Immunohistochemical Localization of Deoxycytidine Kinase. Clin. Cancer Res., November 15, 2006; 12(22): 6863 - 6863. [Full Text] [PDF]